Business question from Michael Connarty (Labour) in the House of Commons on Thursday, 23 November 2006. It occurred during Business statement on Business of the House.
Business of the House
Will my right hon. Friend intercede and ask the Government seriously to consider the recommendation of the Alzheimer’s Society that the National Institute for Health and Clinical Excellence should broaden its remit so that the second-class citizens in England who are about to be denied drugs such as Aricept for mild dementia can be provided with those drugs, as patients in Scotland are? The Government’s remit for NICE appears to be more about money than medical science.
Secondary information
- Type
- Proceeding contribution
- Reference
- 453 c694
- Session
- 2006-07
- Chamber / Committee
- House of Commons chamber
- Subjects
- Devolution Alzheimer's disease Finance Drugs Medical treatments National Institute for Health and Care Excellence Scotland Donepezil
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2024-11-28 21:04:10 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1188591/-question
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1188591/-question
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1188591/-question